PEPGEN INC. - COMMON S

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

14 May 2024 15:02:00 By Nasdaq GlobeNewswire

PepGen to Participate in Upcoming Investor Conferences

13 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

13 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

06 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

04 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

07 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

17 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

15 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

08 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

12 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology

27 Sep 2023 15:16:08 By Nasdaq GlobeNewswire

PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

06 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

06 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference

01 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

08 Aug 2023 07:15:00 By Nasdaq GlobeNewswire

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

13 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

30 May 2023 15:05:00 By Nasdaq GlobeNewswire